The biotech company Nuage Therapeutics, a member of CATALONIA.HEALTH, has received a capital injection of €1.8 million. This funding has been obtained through CDTI Innovation's Innvierte programme and with the participation of the international fund Sofinnova Capital X of Sofinnova Partners.

This financial contribution will allow Nuage to advance in the development of new drugs aimed at therapeutic targets traditionally considered untreatable, such as intrinsically disordered proteins (IDPs), related to serious diseases such as cancer, which until now have remained out of reach of conventional treatments.

In addition, the company has developed a breakthrough in-house technology platform capable of reconstituting these IDPs into structured secondary forms, which opens a new path for the design of therapeutic molecules capable of interacting. This advancement represents a paradigm shift in the field of drug discovery, as IDPs have historically been dismissed as viable targets due to their flexible nature and the difficulty of modulating function through small molecule compounds.

The company, currently led by Stuart Hughes, is focused on turning this technology into real therapeutic solutions for patients with unmet medical needs. With this new round of funding, Nuage Therapeutics aims to accelerate the preclinical development of its first therapeutic candidate in oncology and move into the regulatory and clinical phases.